pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2015-25-6-693-697pulmo-647Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESДиагностическая и прогностическая ценность N-концевого предшественника натрийуретического пептида C-типа у больных хронической обструктивной болезнью легких с легочной гипертензиейDiagnostic and prognostic values of N-terminal pro-C type natriuretic peptide in patients with COPD and pulmonary hypertensionГайнитдиноваВ. В.GaynitdinovaV. V.

к. м. н., доцент кафедры терапии и клинической фармакологии ИПО ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2722385

PhD, Associate Professor at Department of Therapy and Clinical Pharmacology, Bashkir State Medical University; tel.: (347) 2722385

ivv_08@mail.ruАвдеевС. Н.SharafutdinovaL. A.

д. м. н., проф., руководитель клинического отдела ФГУ «НИИ пульмонологии» ФМБА России; тел. / факс: (495) 4655264

MD, Professor, Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 4655264

serg_avdeev@list.ruШарафутдиноваЛ. А.AvdeevS. N.

к. б. н., доцент кафедры физиологии человека и зоологии биологического факультета ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2299671

PhD in Biology, Associate Professor at Department of Human Physiology and Zoology, Biological Faculty, Bashkir State University; tel.: (347) 2299671

sharafla@yandex.ruГубайдуллинаР. Я.GubaydullinaR. Ya.

врач отделения функциональной диагностики ГБУЗ РБ «Городская клиническая больница № 21, г. Уфа»; тел. (347) 2323288

a physician at Department of Functional Diagnosis, State City Clinical Hospital N 21; tel.: (917) 7754070

rasimag@gmail.comГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России: 450000, Россия, Уфа, ул. Ленина, 3РоссияBashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, PussiaRussian FederationФГУ НИИ пульмонологии ФМБА России: 105077, Москва, ул. 11#я Парковая, 32, корп. 4РоссияBashkir State University: 32, Z.Validi str., Ufa, 450076, Bashkortostan Republic, RussiaRussian FederationГБОУ ВПО «Башкирский государственный университет»: 450076, Россия, Уфа, ул. З.Валиди, 32РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, RussiaRussian FederationГБУЗ РБ «Городская клиническая больница № 21, г. Уфа»: 450071, Республика Башкортостан, Уфа, Лесной проезд, 3РоссияState City Clinical Hospital N 21; 3g, Lesnoy passage, Ufa, 450071, Bashkortostan Republic, RussiaRussian Federation201528022016256693697Copyright © Гайнитдинова В.В., Авдеев С.Н., Шарафутдинова Л.А., Губайдуллина Р.Я., 20162016Гайнитдинова В.В., Авдеев С.Н., Шарафутдинова Л.А., Губайдуллина Р.Я.Gaynitdinova V.V., Sharafutdinova L.A., Avdeev S.N., Gubaydullina R.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/647

Проведено исследование Nконцевого предшественника натрийуретического пептида Стипа (NTproCNP) у больных (n = 47: 44 мужчины, 3 женщины; средний возраст – 59,49 ± 0,63 года, длительность заболевания – 13,7 ± 0,63 года, индекс курения – 23,09 ± 0,93 пачколет, индекс массы тела – 27,22 ± 9,06 м / кг2) хронической обструктивной болезнью легких (ХОБЛ) II–IV степени тяжести по GOLD (2011). В зависимости от наличия и степени повышения среднего давления в легочной артерии (СДЛА) пациенты были разделены на 3 группы: 1я (n = 21) – без легочной гипертензии (ЛГ) (СДЛА < 40 мм рт. ст.); 2я (n = 16) – с нетяжелой ЛГ (СДЛА 40–55 мм рт. ст.); 3я (n = 10) – с тяжелой ЛГ (СДЛА > 55 мм рт. ст.). Отмечены статистически значимые различия (p1–2 = 0,001; p2–3 = 0,001; p1–3 < 0,001) значений NTproCNP у больных без ЛГ – 1,42 ± 0,03 пг / мл, с нетяжелой (4,14 ± 0,51 пг / мл) и тяжелой (5,26 ± 0,21 пг / мл) ЛГ. Выявлены значимая корреляционная взаимосвязь СДЛА с концентрацией NTproCNP (r = 0,53; p < 0,05) и высокая диагностическая значимость определения NTproCNP для прогнозирования тяжелой и нетяжелой ЛГ у больных ХОБЛ.

The aim of this study was to investigate diagnostic and prognostic values of Nterminal proC type natriuretic peptide in patients with stage II – IV chronic obstructive pulmonary disease (COPD) (GOLD, 2011).

Methods

Methods. Patients with stage II – IV COPD (n = 47; 44 males, mean age, 59.49 ± 0.63 years; disease duration, 13.7 ± 0.63 years; smoking history, 23.09 ± 0.93 packyears; body mass index, 27.22 ± 9.06 kg / m–2) were involved in the study. The patients were divided according to presence or absence of pulmonary hypertension (PH): patients without PH (n = 21; systolic pulmonary artery pressure (sPAP) < 40 mmHg), patients with mild PH (n = 16, sPAP 40 – 55 mmHg) and patients with severe PH (n = 10; sPAP > 55 mmHg).

Results

Results. NTproCNP levels differed significantly between patients without PH (1.42 ± 0.03 pg / mL), patients with mild PH (4.14 ± 0.51 pg / mL) and patients with severe PH (5.26 ± 0.21 pg / mL) (p1–2 = 0.001; p2–3 = 0.001; p1–3 < 0.001). sPAP was related to NTproCNP level (r = 0.53; p < 0.05).

Conclusion

Conclusion. NTproCNP had a high diagnostic value for predicting severe and nonsevere PH in COPD patients.

хроническая обструктивная болезнь легкихлегочная гипертензияNконцевой предшественник натрийуретического пептида Стипа.chronic obstructive pulmonary diseasepulmonary hypertensionNterminal proC type natriuretic peptideReferencesWeitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.Andersen K.H., Iversen M., Kjaergaard J. et al. Prevalence, predictors and survival in pulmonary hypertension related to endstage chronic obstructive pulmonary disease. Heart Lung Transplant. 2012; 31: 373–380.Andersen K.H., Iversen M., Kjaergaard J. et al. Prevalence, predictors and survival in pulmonary hypertension related to endstage chronic obstructive pulmonary disease. Heart Lung Transplant. 2012; 31: 373–380.Burrows B. Arterial oxygenation and pulmonary hemodynamics in patients with chronic airways obstruction. Am. Rev. Respir. Dis. 1974; 110: 64–70.Burrows B. Arterial oxygenation and pulmonary hemodynamics in patients with chronic airways obstruction. Am. Rev. Respir. Dis. 1974; 110: 64–70.Wright J.L. Relationship of pulmonary arterial pressure and air flow obstruction to emphysema. J. Appl. Physiol. 1993; 74: 1320–1324.Wright J.L. Relationship of pulmonary arterial pressure and air flow obstruction to emphysema. J. Appl. Physiol. 1993; 74: 1320–1324.Santos S., Peinado V.I., Ramirez J. et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur. Respir. J. 2002; 19: 632–638.Santos S., Peinado V.I., Ramirez J. et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur. Respir. J. 2002; 19: 632–638.Hale K.A, Ewing S.L., Gosnell B.A. et al. Lung disease in long term cigarette smokers with and without chronic airflow obstruction. Am. Rev. Respir. Dis. 1984; 130: 716–721.Hale K.A, Ewing S.L., Gosnell B.A. et al. Lung disease in long term cigarette smokers with and without chronic airflow obstruction. Am. Rev. Respir. Dis. 1984; 130: 716–721.Peinado V.I., Barbera J.A., Abate P. et al. Infl ammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1605–1611.Peinado V.I., Barbera J.A., Abate P. et al. Infl ammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1605–1611.DinhXuan A.T., Higenbottam T.W., Clelland C.A. et al. Impairment of endotheliumdependent pulmonaryartery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991; 324: 1539–1547.DinhXuan A.T., Higenbottam T.W., Clelland C.A. et al. Impairment of endotheliumdependent pulmonaryartery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991; 324: 1539–1547.Peinado V.I., Barbera J.A., Ramirez J. et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am. J. Physiol. 1998; 274: 908–913.Peinado V.I., Barbera J.A., Ramirez J. et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am. J. Physiol. 1998; 274: 908–913.Santos S., Peinado V.I., Ramirez J. et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1250–1256.Santos S., Peinado V.I., Ramirez J. et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1250–1256.Sellitti D.F. Regulation of Ctype natriuretic peptide expression. Peptides. 2011; 32: 1964–1971.Sellitti D.F. Regulation of Ctype natriuretic peptide expression. Peptides. 2011; 32: 1964–1971.Cazzola M., MacNee W., Martinez F.J. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.Cazzola M., MacNee W., Martinez F.J. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.Seeger W., Adir Y., Barber? J.A. et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl. D): 110–116.Seeger W., Adir Y., Barber? J.A. et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl. D): 110–116.Quanjer Ph.H., Tammelling G., Gotes J.E. et al. Lung volumes and forced ventilator flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40.Quanjer Ph.H., Tammelling G., Gotes J.E. et al. Lung volumes and forced ventilator flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40.Chaouat A., Naeije R., Weitzenblum E. Pulmonary hyperten sionin COPD. Eur. Respir. J. 2008; 32: 1371–1385.Chaouat A., Naeije R., Weitzenblum E. Pulmonary hyperten sionin COPD. Eur. Respir. J. 2008; 32: 1371–1385.Scotland R.S., Ahluwalia A., Hobbs A.J. Ctype natriuretic peptide in vascular physiology and disease. Pharmacol. Ther. 2005; 105: 85–93.Scotland R.S., Ahluwalia A., Hobbs A.J. Ctype natriuretic peptide in vascular physiology and disease. Pharmacol. Ther. 2005; 105: 85–93.Almeida F.M., Suzuki M., Scarborough R.M. et al. Clearance function of type C receptors of atrial natriuretic factor in rats. Am. J. Physiol. 1989; 256: 469–475.Almeida F.M., Suzuki M., Scarborough R.M. et al. Clearance function of type C receptors of atrial natriuretic factor in rats. Am. J. Physiol. 1989; 256: 469–475.Vlachopoulos C., Ioakeimidis N., TerentesPrintzios D. et al. Aminoterminal proCtype natriuretic peptide is associated with arterial stiffness, endothelial function and early atheroscle rosis. Atherosclerosis. 2010; 211: 649–655Vlachopoulos C., Ioakeimidis N., TerentesPrintzios D. et al. Aminoterminal proCtype natriuretic peptide is associated with arterial stiffness, endothelial function and early atheroscle rosis. Atherosclerosis. 2010; 211: 649–655Soeki T., Kishimoto I., Okumura H. et al. Ctype natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2005; 5: 608–616.Soeki T., Kishimoto I., Okumura H. et al. Ctype natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2005; 5: 608–616.Suga S., Nakao K., Itoh H. et al. Endothelial production of C type natriuretic peptide and its marked augmentation by trans forming growth factorbeta. Possible existence of «vascular natriuretic peptide system». J. Clin. Invest. 1992; 90: 1145–1149.Suga S., Nakao K., Itoh H. et al. Endothelial production of C type natriuretic peptide and its marked augmentation by trans forming growth factorbeta. Possible existence of «vascular natriuretic peptide system». J. Clin. Invest. 1992; 90: 1145–1149.Naruko T., Itoh A., Haze K. et al. Ctype natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis. 2005;181: 241–250.Naruko T., Itoh A., Haze K. et al. Ctype natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis. 2005;181: 241–250.Peltonen T.O., Taskinen P., Soini Y. et al. Distinct downregulation of Ctype natriuretic peptide system in human aortic valve stenosis. Circulation. 2007; 116: 1283–1289.Peltonen T.O., Taskinen P., Soini Y. et al. Distinct downregulation of Ctype natriuretic peptide system in human aortic valve stenosis. Circulation. 2007; 116: 1283–1289.Christoffersen C., Bartels E.D., Nielsen L.B. Heart specific up regulation of genes for Btype and Ctype natriuretic peptide receptors in diabetic mice. Eur. J. Clin. Invest. 2006; 36: 69–75.Christoffersen C., Bartels E.D., Nielsen L.B. Heart specific up regulation of genes for Btype and Ctype natriuretic peptide receptors in diabetic mice. Eur. J. Clin. Invest. 2006; 36: 69–75.Suga S., Itoh H., Komatsu Y. et al. Cytokineinduced Ctype natriuretic peptide (CNP) secretion from vascular endothelial cellsevidence for CNP as a novel autocrine / paracrine regulator from endothelial cells. Endocrinology. 1993; 133: 3038–3041.Suga S., Itoh H., Komatsu Y. et al. Cytokineinduced Ctype natriuretic peptide (CNP) secretion from vascular endothelial cellsevidence for CNP as a novel autocrine / paracrine regulator from endothelial cells. Endocrinology. 1993; 133: 3038–3041.Cargill R.I., Barr C.S., Coutie W.J. et al. Ctype natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax. 1994; 49: 1247–1249.Cargill R.I., Barr C.S., Coutie W.J. et al. Ctype natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax. 1994; 49: 1247–1249.Неклюдова Г.В., Авдеев С.Н., Баймаканова Г.Е. Хроническая обструктивная болезнь легких и легочная гипертензия: мозговой натрийуретический пептид как маркер легочной гипертензии. Пульмонология. 2013; 3: 31–35. / Neklyudova G.V., Avdeev S.N., Baymakanova G.E. Chronic obstructive pulmonary disease and pulmonary hypertension: brain natriuretic peptide as a marker of pulmonary hyperten sion. Pul'monologiya. 2013; 3: 31–35 (in Russian).Неклюдова Г.В., Авдеев С.Н., Баймаканова Г.Е. Хроническая обструктивная болезнь легких и легочная гипертензия: мозговой натрийуретический пептид как маркер легочной гипертензии. Пульмонология. 2013; 3: 31–35. / Neklyudova G.V., Avdeev S.N., Baymakanova G.E. Chronic obstructive pulmonary disease and pulmonary hypertension: brain natriuretic peptide as a marker of pulmonary hyperten sion. Pul'monologiya. 2013; 3: 31–35 (in Russian).

The authors declare that there are no conflicts of interest present.